TRENTON, NJ – The New Jersey Department of Health (NJDOH) is addressing public health concerns following the confirmation of a measles case earlier this year and the investigation of eight …
"vaccine"
-
-
US is ’18 months or so’ away from finding bird flu vaccine, says agriculture secretary
by Reutersby ReutersBy Leah Douglas (Reuters) – The U.S. Department of Agriculture is “18 months or so” away from identifying a vaccine for the current strain of bird flu and is developing …
-
‘Who Can We Talk To?’: White House Leaned On Amazon To Suppress Vaccine ‘Propaganda,’ Emails Show Jason Cohen on February 5, 2024 President Joe Biden’s White House influenced Amazon in …
-
By Eva Mathews (Reuters) -GSK beat market estimates for fourth-quarter results on Wednesday, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer …
-
By Michael Erman and Bhanvi Satija (Reuters) -Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year …
-
(Reuters) -The U.S. Centers for Disease Control and Prevention (CDC) on Thursday issued an alert urging healthcare providers to increase immunization coverage for influenza, COVID-19 and respiratory syncytial virus (RSV). …
-
(Reuters) -Moderna said its Chief Commercial Officer Arpa Garay has stepped down from the role and CEO Stephane Bancel will look over sales and marketing, sending the shares of the …
-
Exclusive-World animal health body warns of swine fever vaccine risks as Vietnam readies exports
by Reutersby ReutersBy Francesco Guarascio, Khanh Vu and Mikhail Flores HANOI/MANILA (Reuters) -The World Organisation for Animal Health (WOAH) is warning that more testing of African swine fever vaccines is needed, triggered …
-
By Jonathan Stempel (Reuters) – Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. …
-
By Julie Steenhuysen CHICAGO (Reuters) – Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, …
-
By Patrick Wingrove and Bhanvi Satija (Reuters) -COVID-19 vaccine maker Novavax on Thursday beat market estimates for quarterly revenue, boosted by U.S. government grants to help cover the expense of …
-
FRANKFURT (Reuters) – BioNTech has cut its 2023 revenue target by about 1 billion euros ($1.1 billion) on lower demand for the COVID-19 vaccine made with Pfizer but said the …
-
By Patrick Wingrove and Leroy Leo (Reuters) -Moderna on Thursday said its 2023 sales would only hit the low end of its $6 billion to $8 billion forecast, reflecting weaker …
-
By Michael Erman (Reuters) – Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an …
-
(Reuters) – Moderna on Monday reaffirmed its forecast of $6 billion to $8 billion in COVID vaccine sales for the year, after rival Pfizer slashed forecast for its vaccine last …
-
By Michael Erman, Ludwig Burger and Manas Mishra (Reuters) -Pfizer set off a fresh round of concern about the size of the U.S. COVID-19 vaccine and treatment market in the …
-
By Patrick Wingrove (Reuters) – More than 7 million Americans had rolled up their sleeves for the updated COVID-19 vaccines as of Wednesday, according to the U.S. Department of Health …
-
By Ahmed Aboulenein and Michael Erman (Reuters) -Around 4 million Americans received the updated COVID-19 shots in September, according to the U.S. Department of Health and Human Services (HHS), even …
-
By Ludwig Burger, Niklas Pollard STOCKHOLM (Reuters) -Hungarian scientist Katalin Kariko and U.S. colleague Drew Weissman, who met in line for a photocopier before making mRNA molecule discoveries that paved …
-
By Michael Erman (Reuters) -The U.S. Centers for Disease Control and Prevention (CDC) on Friday recommended Pfizer’s respiratory syncytial virus (RSV) vaccine for women in the middle of the third …
-
(Reuters) – The U.S. National Institutes of Health (NIH) said on Friday that it has begun an early-stage study on its experimental vaccine targeting six strains of influenza virus. The …
-
(Reuters) -Contract research firm ICON Plc said on Wednesday it is partnering with the U.S. government for a clinical trial to test the effectiveness of next generation COVID-19 vaccine candidates. …
-
By Bhanvi Satija and Michael Erman (Reuters) -The U.S. Centers for Disease Control and Prevention director on Tuesday signed off on broad use of updated COVID-19 vaccines approved by the …
-
By Michael Erman (Reuters) -The U.S. drug regulator authorized updated COVID-19 vaccines from Pfizer and its partner BioNTech as well as from Moderna this week as the country prepares to …
-
(Reuters) – U.S. COVID vaccine manufacturers set list prices for their shots between $120 and $130 per dose, company executives said at an advisory panel meeting of U.S. Centers for …